Jejunostomy in the palliative treatment of gastric cancer: A clinical prognostic score

Table 2 Characteristics of jejunostomy patients according to the risk group-score development cohort (n = 40)

Variables	J1-score development cohort		P value
	Low-risk	High-risk
	n = 14 (%)	n = 26 (%)
Sex			0.507
Female	6 (42.9)	14 (53.8)
Male	8 (57.1)	12 (46.2)
Age (years)			0.954
mean (SD)	62.0 (15.0)	61.7 (12.9)
BMI (kg/m2)			0.101
mean (SD)	20.4 (2.7)	22.4 (3.9)
CCI			0.885
0	10 (71.4)	18 (69.2)
≥ 1	4 (286)	8 (30.8)
ASA class			0.507
I/II	8 (57.1)	12 (46.2)
III/IV	6 (42.9)	14 (53.8)
Hemoglobin (g/dL)			0.456
mean (SD)	11.1 (1.9)	10.5 (2.0)
Albumin (g/dL)			0.123
mean (SD)	3.7 (0.6)	3.3 (0.6)
NLR			0.001
mean (SD)	3.03 (1.58)	7.46 (5.22)
Tumor size (cm)			0.18
mean (SD)	6.9 (2.1)	8.3 (3.4)
Presence of ascites on CT			0.48
Absent	6 (42.9)	7 (26.9)
Present	8 (57.1)	19 (73.1)
Lauren type			1
Intestinal	4 (28.6)	6 (23.1)
Diffuse/mixed	9 (64.3)	17 (65.4)
Undetermined	1 (7.1)	3 (11.5)
Number of disease sites			0.408
One (only locoregional)	6 (42.9)	7 (26.9)
Two or more	8 (57.1)	19 (73.1)
POC			0.075
No POC/Clavien 1-2	14 (100)	19 (73.1)
Clavien 3-5	0 (0)	7 (26.9)
Length of hospital stay (days)			0.452
Median (IQR)	4.5 (1.7-6.3)	5 (2.7-9.5)
Palliative treatment-1st line			0.257
No	6 (42.9)	16 (61.5)
Yes	8 (57.1)	10 (38.5)
30-d mortality			0.013
No	13 (92.9)	13 (50)
Yes	1 (7.1)	13 (50)
90-d mortality			< 0.001
No	12 (85.7)	7 (26.9)
Yes	2 (14.3)	19 (73.1)

SD: Standard deviation; IQR: Interquartile range; POC: Postoperative complication; CCI: Charlson's comorbidity index; CT: Computed tomography; NLR: Neutrophil lymphocyte ratio; ASA: American Society of Anesthesiologists; BMI: Body mass index.